March 21st 2024
Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.
March 12th 2024
Francine Brinkhuis, MSc, and Lourens T. Bloem, PharmD, MSc, highlight findings from an analysis of the benefit and revenue for EU-approved oncology drugs.
Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.
March 11th 2024
Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.
March 8th 2024
Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.
Suzanne B. Coopey, MD, highlights the initial challenges that she experienced during her residency and expands on the support found in the field.
March 6th 2024
The EMA has received a type II variation application for an indication extension of D-VRd for the treatment newly diagnosed multiple myeloma.
March 5th 2024
China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.
March 4th 2024
Katrina S. Pedersen, MD, MS, shares updates in the treatment of gastrointestinal cancers, including biliary tract cancer and neuroendocrine tumors.
Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.
March 3rd 2024
Katrina S. Pedersen, MD, MS, details how the treatment of patients with gastrointestinal malignancies is evolving and notes notable trials as well as approvals.
March 2nd 2024
Neoadjuvant tislelizumab plus axitinib demonstrated clinical efficacy and safety in patients with nonmetastatic clear cell renal cell carcinoma.
February 28th 2024
The FDA granted an orphan drug designation to LUT014 for the treatment of EGFR inhibitor–induced acneiform rash.
February 26th 2024
Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.
The European Medicines Agency’s CHMP has recommended the approval of tislelizumab in the first- and second-line for non–small cell lung cancer.
February 23rd 2024
Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.
February 21st 2024
Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.
February 20th 2024
Burton Eliot Appel, MD, discusses the importance of recognizing Childhood Cancer Day in pediatric patients with cancer.
Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.
A sNDA for adagrasib plus cetuximab in advanced KRAS G12C–mutated colorectal cancer was granted priority review by the FDA.